VL
AMPH icon

Vima LLC’s Amphastar Pharmaceuticals AMPH Stock Holding History

Vima LLC’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-290
Closed -$17.9K – 449
2023
Q4 		$17.9K Buy
+290
New +$15.2K 0.04% 197

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Vima LLC's AMPH Position: Q1 2024 in Review

Vima LLC sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 290 shares — an estimated $17.9K sold.

Vima LLC first reported a position in AMPH in Q4 2023 and held it in 1 quarter. The position peaked at $17.9K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Vima LLC reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Vima LLC sold 290 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $17.9K.
  • Vima LLC first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Vima LLC's Amphastar Pharmaceuticals position peaked at $17.9K in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Vima LLC's 13F filing for Q1 2024, filed 17 May 2024.